Posters

Visual outcome of intravitreal triamcinolone acetinoide injection at the end of phacovitrectomy for diabetic vitreous haemorrhage

Poster Details

First Author: A.Lotfy EGYPT

Co Author(s):    A. Abdel Rahman   A. Samir                 

Abstract Details

Purpose:

This study aims to evaluate the visual, clinical outcome and complications of intravitreal triamcinolone acetonide (IVT) injections at the end of phacovitrectomy in patients with diabetic vitreous hemorrhage.

Setting:

Zagazig University Hospitals,ophthalmology department, Egypt

Methods:

This is a prospective comparative case study comprised of 22 eyes from 22 patients who underwent phaco vitrectomy for diabetic vitreous hemorrhage (VH) with or without tractional retinal detachment (TRD). IVT (4 mg/0.1 ml) injection was done for 11 eyes (11patients) at the end of vitrectomy, and no injection was done for 11 eyes (11 patients). Main outcome measures were best-corrected visual acuity (BCVA), intraocular pressure (IOP), and incidence of postoperative VH and reoperation with at least 3 months of follow-up.

Results:

Early postoperative VH within 1 month postoperatively occurred in 9.1% from the IVT group and 27.27% from the control group. The rate of early postoperative VH was significantly lower in the IVT group than the control group (p=0.006). Late postoperative VH after 1 month postoperatively occurred in 18.18% from the IVT group and 27.27% from the control group. There was no difference between the two groups (P=0.341). BCVA of the IVT, and control group at postoperative months 1 and 3 significantly improved from the preoperative BCVA (p<0.01). There was significant difference for BCVA between the two groups at one month follow-up period (p>0.05). There was no difference for BCVA between the two groups at 3 ms follow-up period (p>0.05).

Conclusions:

IVT injection at the end of diabetic vitrectomy is a useful adjunctive therapy for reducing early postoperative VH compared to the control group, however it did not affect the final visual outcome.

Financial Disclosure:

NONE